Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 6/20 | 0.64 |
| ▸ | PTGDR | Q13258 | 5/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | CCR2 | P41597 | 1/20 | 0.50 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.48 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 2/20 | 0.45 |
| ▸ | HTR6 | P50406 | 1/20 | 0.45 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7652408 | 0.89 | NOTUM (0.56) | PTGER4PTGDRADRA1DNOTUMPTGER2 | |
| SCHEMBL987890 | 0.88 | PTGER4 (0.51) | PTGER4PTGDRCCR2EGLN1NOTUM | |
| SCHEMBL12584024 | 0.84 | PTGER4 (0.48) | PTGER4PTGDRNOTUMHTR6PTGER2 | |
| SCHEMBL989493 | 0.81 | CHRM1 (0.50) | PTGER4PTGDREGLN1NOTUMPTGER2 | |
| SCHEMBL12900314 | 0.81 | FABP4 (0.50) | PTGER4PTGDRNOTUMKMT2ASMN1; SMN2 | |
| SCHEMBL12900317 | 0.81 | NOTUM (0.51) | PTGER4PTGDRKDM4ENOTUMKMT2A | |
| SCHEMBL12000764 | 0.81 | PTGER4 (0.66) | PTGER4PTGDRKDM4EKMT2ASMN1; SMN2 | |
| SCHEMBL12900285 | 0.81 | PTGER4 (0.67) | PTGER4PTGDRCCR2ADRA1DMAOB | |
| SCHEMBL1748992 | 0.80 | PTGER4 (1.00) | PTGER4PTGDRPTGER2 | |
| SCHEMBL12000743 | 0.80 | PTGER4 (1.00) | PTGER4PTGDRPTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | APP, PSEN2, PSEN1 | PTGER4 1561/4885PTGDR 2583/4885KDM4E 4461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.